Images from the lab, from fluorescence microscopy of cells and nuclei to 3D DNA traces and polymer simulations of chromatin.

NTNU · Department of Chemistry and Biomedical Science

Beckwith Lab

Genome Architecture and Precision Medicine

We build microscopy methods to study genome organization in single cells, and use them to study cancer, especially multiple myeloma, where we are working on new diagnostic and prognostic approaches.

About the lab

My lab is newly started at NTNU in Trondheim, Norway and focuses on two biological areas that both build on a basis of new microscopy approaches: how genomes are organized, and how to diagnose and treat multiple myeloma.

On the basic‑science side, we want to understand how chromatin is physically arranged in the nucleus: how loop‑extruding motors interact with the transcription machinery shape the genome in individual cells, especially during transcription. To see this directly we use and develop microscopy methods, including LoopTrace (non‑denaturing 3D DNA tracing) and multiplexed cyclic imaging to study chromatin folding at the level of single alleles. We combine these with computational models to describe mechanisms of genome function.

On the clinical side, we work on multiple myeloma, a bone‑marrow cancer that can be treated but not yet cured. Together with clinicians at St. Olavs Hospital we are working towards establishing ex vivo drug screening on patient cells with single‑cell imaging readouts, new approaches to characterize molecular profiles of single cells and ways to catch and profile the rare myeloma cells that circulate in blood.

Research

Basic research

How chromosomes fold

Roughly two metres of DNA has to fit into a nucleus a few micrometres across and still be read correctly. To see how this works, we trace chromosomal DNA directly in structurally preserved cells. LoopTrace, our non‑denaturing 3D DNA‑tracing method, locates genomic loci with high spatial and genomic resolution. This lets us directly see the loops made by SMC complexes (cohesin and condensin) in individual cells, rather than inferring them from population averages. With this approach we have studied Condensin-dependent mitotic chromatin folding, and Cohesin-dependent interfase chromatin organization.

  • VASE. Next we want to look at super‑enhancers, clusters of regulatory elements that drive strong expression of cell‑identity genes and oncogenes. We ask how they are organized at the nanoscale, how that organization changes as transcription switches on and off, and whether biophysical models can predict what we see.
  • Nanoscale DNA tracing
  • Super‑enhancer biology
  • Live‑cell & single‑molecule imaging
  • Polymer biophysics

Translational research

Multiple myeloma

Multiple myeloma is a cancer of plasma cells in the bone marrow. It looks quite different from patient to patient, and nearly everyone eventually relapses, so better ways to choose treatments and to follow the disease are needed. We have three projects in this direction, together with clinicians and nanotechnologists in Trondheim:

  • EPIMYELOM. We are developing methods to test current and noveldrugs on patients’ bone‑marrow cells ex vivo, and read out single‑cell molecular profiles. The aim is to work out which patient subgroups are likely to respond and develop personalized treatment strategies.
  • PAPMY. Can myeloma cells circulating in the blood stand in for a bone‑marrow biopsy? We are testing whether they can be used for prognosis and for monitoring treatment response.
  • NEOPRAD. Circulating myeloma cells are rare, so catching them is the hard part. We combine magnetic‑nanoparticle capture with automated multiplexed microscopy to pull them out of blood and profile rare cell populations.
  • Circulating tumour cells
  • Ex vivo drug screening
  • Multiplexed DNA‑FISH
  • Bioimaging diagnostics

Funding

Helse Midt-Norge Samarbeidsorganet HMN–NTNU
EPIMYELOM — Coupled drug screening and multimodal profiling of multiple myeloma 2025–2028 · PI · image‑based ex vivo drug screening
St. Olavs hospital St. Olavs Foundation
PAPMY — Painless Precision in Myeloma Study 2025–2027 · Co‑PI · circulating tumour cells for prognosis & response
Research Council of Norway (Forskningsrådet) FRIPRO
VASE — Visualizing active super‑enhancer organization and function 2026–2030 · PI · single‑cell nanoscale imaging
Research Council of Norway (Forskningsrådet) Emerging Tech
NEOPRAD — Nanoparticle capture & optical profiling of rare tumour cells 2026–2029 · PI · diagnostic platform

Publications

Selected papers

Full publication list

Team

Open positions

Currently we have no posted positions.

Reach out if you would like to explore other ways to join our lab.

Code

See links in our publications for current code and data depositions. Updated repositories from our research will be collected on NTNU Git; the first ones are on their way.

git.ntnu.no/BeckwithLab

Contact

Kai Sandvold Beckwith

Associate Professor
Department of Chemistry and Biomedical Science
Faculty of Natural Sciences, NTNU

kai.beckwith@ntnu.no
NTNU profile

NTNU
Department of Chemistry and Biomedical Science
7491 Trondheim, Norway